Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “MSI-H/dMMR Tumors”

126 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 126 results

Testing effectiveness (Phase 2)Looking for participantsNCT07140679
What this trial is testing

Immunotherapy (Toripalimab) for Reducing Recurrence Risk After Surgery for Mismatch Repair Deficient Stage IIB, IIC, or III Colon Cancer

Who this might be right for
Localized Colon CarcinomaStage IIB Colon Cancer AJCC v8Stage IIC Colon Cancer AJCC v8+1 more
Emory University 40
Testing effectiveness (Phase 2)Looking for participantsNCT03667170
What this trial is testing

KN035 for dMMR/MSI-H Advanced Solid Tumors

Who this might be right for
Solid Tumor
3D Medicines (Sichuan) Co., Ltd. 200
Early research (Phase 1)Study completedNCT04242199
What this trial is testing

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors

Who this might be right for
Advanced Solid TumorMSI-H/dMMR TumorsCutaneous Squamous Cell Carcinoma+9 more
Incyte Corporation 182
Testing effectiveness (Phase 2)WithdrawnNCT04001101
What this trial is testing

Anti-PD-1 +/- RT for MSI-H Solid Tumors

Who this might be right for
Microsatellite Instability HighMismatch Repair DeficiencyColorectal Cancer
University of Colorado, Denver
Testing effectiveness (Phase 2)Active Not RecruitingNCT07523763
What this trial is testing

Neoadjuvant Low-dose Immunotherapy in Locally Advanced MMR-deficient Colorectal Cancer

Who this might be right for
Colorectal Cancer (MSI-H)Colorectal Cancer (CRC)
Blokhin's Russian Cancer Research Center 30
Testing effectiveness (Phase 2)UnknownNCT04866862
What this trial is testing

Fruquitinib Combined With Camrelizumab in Non MSI-H/dMMR Refractory Colorectal Cancer

Who this might be right for
Colorectal Neoplasm
The First Affiliated Hospital with Nanjing Medical University 32
Early research (Phase 1)Ended earlyNCT05909995
What this trial is testing

Interventional Study of INCB 99280 With Ipilimumab in Participants With Select Solid Tumors

Who this might be right for
MelanomaHepatocellular Carcinoma (HCC)Renal Cell Carcinoma (RCC)+3 more
Incyte Corporation 8
Large-scale testing (Phase 3)Active Not RecruitingNCT05890742
What this trial is testing

A Clinical Trial Evaluating the Efficacy and Safety of IBI310 in Combination With Sintilimab, for Neoadjuvant Treatment of MSI-H/dMMR Resectable Colon Cancer

Who this might be right for
MSI-H
Innovent Biologics (Suzhou) Co. Ltd. 453
Testing effectiveness (Phase 2)Active Not RecruitingNCT05879822
What this trial is testing

Evaluate INCB099280 in Participants With Select Solid Tumors Who Are Immune Checkpoint Inhibitor Naive

Who this might be right for
Advanced Solid Tumor
Incyte Corporation 73
Large-scale testing (Phase 3)Active Not RecruitingNCT02997228
What this trial is testing

Testing the Addition of Atezolizumab to Combination Chemotherapy or Atezolizumab Alone for Metastatic Colon or Rectal Cancer, the COMMIT Study

Who this might be right for
Metastatic Colorectal AdenocarcinomaStage IV Colorectal Cancer AJCC v7
National Cancer Institute (NCI) 120
Large-scale testing (Phase 3)Looking for participantsNCT06686576
What this trial is testing

Neoadjuvant QL1706 in Participants With Untreated dMMR/MSI-H Resectable Colon Cancer

Who this might be right for
Colon Cancer
Qilu Pharmaceutical Co., Ltd. 363
Testing effectiveness (Phase 2)Active Not RecruitingNCT07160647
What this trial is testing

The Efficacy and Safety of Neoadjuvant Therapy With Iparomlimab and Tuvonralimab in Locally Advanced MSI-H/dMMR Colorectal Cancer: An Prospective, Single-Arm Study (Neo-IT)

Who this might be right for
dMMR/MSI-H-type Rectal Adenocarcinoma
Sir Run Run Shaw Hospital 29
Post-approval studies (Phase 4)Not Yet RecruitingNCT06897527
What this trial is testing

Evaluate the Safety of Dostarlimab in Adult Participants in India With Recurrent or Advanced Endometrial Cancer (EC)

Who this might be right for
Neoplasms, Endometrial
GlaxoSmithKline 100
Testing effectiveness (Phase 2)Active Not RecruitingNCT04751370
What this trial is testing

Testing Nivolumab and Ipilimumab With Short-Course Radiation in Locally Advanced Rectal Cancer

Who this might be right for
Locally Advanced Rectal AdenocarcinomaStage II Rectal Cancer AJCC v8Stage III Rectal Cancer AJCC v8
National Cancer Institute (NCI) 31
Testing effectiveness (Phase 2)Active Not RecruitingNCT04895722
What this trial is testing

Evaluation of Co-formulated Pembrolizumab/Quavonlimab (MK-1308A) Versus Other Treatments in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Cancer (CRC) (MK-1308A-008/KEYSTEP-008)

Who this might be right for
Colorectal Cancer
Merck Sharp & Dohme LLC 302
Testing effectiveness (Phase 2)UnknownNCT05769725
What this trial is testing

Evaluate Serplulimab in Combination With Docetaxel +S-1 VS. Docetaxel +S-1 as Adjuvant Treatment Therapy in Stage IIIc Gastric Cancer

Who this might be right for
Serplulimab,Gastric Cancer, Adjuvant Therapy
RenJi Hospital 70
Not applicableUnknownNCT05645094
What this trial is testing

Neoadjuvant Envafolimab in Resectable and Locally Advanced MSI-H/dMMR Rectal Cancer

Who this might be right for
Locally Advanced Rectal CarcinomaMSI-High
Fudan University 38
Not applicableLooking for participantsNCT06477991
What this trial is testing

The Efficacy of Watch and Wait Strategy or Surgery After Neoadjuvant Immunotherapy for Locally Advanced Colorectal Cancer With dMMR/MSI-H Guided by MRD Dynamic Monitoring: A Single-center, Open-label, Prospective, Phase II Clinical Trial.

Who this might be right for
Clinical Complete Response Rate With Negative MRD
Yunnan Cancer Hospital 22
Testing effectiveness (Phase 2)UnknownNCT04152889
What this trial is testing

Evaluate Camrelizumab in Combination With Docetaxel +S-1 as Adjuvant Treatment Therapy in Stage III Gastric Cancer

Who this might be right for
Gastric Cancer Stage III
RenJi Hospital 20
Testing effectiveness (Phase 2)UnknownNCT03638297
What this trial is testing

PD-1 Antibody Combined With COX Inhibitor in MSI-H/dMMR or High TMB Colorectal Cancer

Who this might be right for
Colorectal Cancer
Sun Yat-sen University 29
Load More Results